Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.

@article{Kudzma2002EffectsOT,
  title={Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.},
  author={David J Kudzma},
  journal={The American journal of managed care},
  year={2002},
  volume={8 16 Suppl},
  pages={S472-82}
}
The thiazolidinediones (TZDs) are a new class of oral antidiabetic agents used in the treatment of type 2 diabetes mellitus. TZDs are selective and potent agonists of peroxisome proliferator-activated receptor-gamma, which is expressed in target tissues for insulin action and in a variety of cells that play an important role in atherosclerosis. TZDs primarily improve glycemic control by reducing insulin resistance in target tissues. Evidence also suggests that the TZDs may have a direct… CONTINUE READING